Two global Phase 3 clinical trials are now testing dazodalibep, Amgen’s experimental therapy for Sjögren’s disease, in two groups of adults. One of the studies is still recruiting participants. One of the trials, called HZNP-DAZ-301 (NCT06104124), has completed enrollment of 651 people with moderate-to-severe systemic (body-wide) Sjögren’s…
People with Sjögren’s disease who received the experimental therapy ianalumab (VAY736) in Phase 3 clinical trials reported greater reductions in disease activity than those given a placebo within two months of starting treatment. That’s according to new data ianalumab’s developer, Novartis, shared at the American College of Rheumatology…
Sjögren’s disease patients found significant relief from debilitating symptoms like dryness, pain, and fatigue after treatment with Johnson & Johnson’s investigational antibody, nipocalimab, in a Phase 2 clinical trial. Full results from the study, dubbed DAHLIAS (NCT04969812), confirmed that nipocalimab treatment, compared to a placebo, not only…
An experimental therapy from Ouro Medicines is being tested in a Phase 1b clinical trial on people who have Sjögren’s disease or idiopathic inflammatory myopathy (IMM), another autoimmune condition. “This study reflects Ouro’s strategy of expanding OM336 development to additional immune-mediated diseases where an ‘immune reset’ approach would…
The investigational therapy telitacicept leads to significant and clinically meaningful reductions in disease activity and patient-reported symptoms among adults with primary Sjögren’s disease, according to new data from a Phase 3 clinical trial conducted in China. The findings — consistent with Phase 2 trial data — were…
A machine learning tool that can analyze certain molecules in stool samples may help to better diagnose primary Sjögren’s disease, according to a new study from researchers in China. The team found that their novel model, using fecal samples, could distinguish primary Sjögren’s patients from healthy individuals with an…
Women with primary Sjögren’s disease often face a combination of problems — key among them a weaker sense of taste and smell, disrupted sleep, and sexual discomfort caused by dryness — that reduce their quality of life. That’s according to a new review of more than a dozen studies,…
Rise Therapeutics plans to launch a Phase 1 clinical trial testing R-2487, its experimental oral therapy for autoimmune diseases, in people with Sjögren’s disease. R-2487, which leverages bacterial proteins to suppress the abnormal immune responses in autoimmune diseases like Sjögren’s, “is disease-modifying, focusing on long-term immune correction rather…
Primary Sjögren’s disease-associated interstitial lung disease (pSjD-ILD) — a form of Sjögren’s disease that’s characterized by scarring in the lungs — tends to lead to worse outcomes in biological males than in females, a new study reports. “Our retrospective study revealed that in patients with pSjD-ILD, male individuals were…
Immune B-cells that contain the receptor protein CD226 may play a role in the development and clinical manifestations of primary Sjögren’s disease, making CD226 a possible target for future treatments, a study reports. Data indicated that people with Sjögren’s had proportionally more CD226-positive B-cells in their bloodstream than their…
Get regular updates to your inbox.
